Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Panome Bio
AddedFeb 15, 2024
UpdatedJun 18, 2026
Panome Bio

Panome Bio

Panome Bio: A next-gen biomarker discovery platform offering comprehensive metabolomics solutions, founded in 2022.

HQ
St. Louis, MO, US
Founded
2022
Overview
Compare
Fundraising
Employees
Website

Panome Bio, founded in 2022 and headquartered in Saint Louis, Missouri, is a next-generation biomarker discovery platform. The company’s core mission is to advance the field of metabolomics by providing comprehensive biomarker analysis services. Panome Bio offers a range of solutions including metabolomics, lipidomics, and proteomics screening through untargeted analysis and proprietary computational methods. Their services cater to researchers and industries focused on understanding complex biological systems and developing new therapeutic strategies.

Notable affiliated people and investors have not been disclosed publicly. However, Panome Bio has made significant strides in the field of biomarker discovery, contributing to advancements in personalized medicine and drug development. The company's innovative approach and cutting-edge technology have positioned it as a key player in the metabolomics market, impacting both academic research and commercial applications.

Panome Bio - Similar Companies

Metabolon logo

Metabolon

metabolon.com

Biomiic logo

Biomiic

Sapient logo

Sapient

sapient.bio

Phenomix Sciences logo

Phenomix Sciences

Panorama Medicine logo

Panorama Medicine

OmicsCraft logo

OmicsCraft

omicscraft.com

BioDatomics logo

BioDatomics

biodatomics.com

Via Scientific logo

Via Scientific

viascientific.com

OmicsChart logo

OmicsChart

omicschart.com

Flexomics logo

Flexomics

flexomics.com

BiomeSense logo

BiomeSense

biomesense.com

PanGenX logo

PanGenX

Protein Dynamic Solutions logo

Protein Dynamic Solutions

pdsbio.com

Epinoma logo

Epinoma

epinoma.com

Micronoma logo

Micronoma

micronoma.com

Panome Bio - Quick Facts

Who are Panome Bio's competitors?

Companies similar to Panome Bio include Metabolon, Biomiic, Sapient and Phenomix Sciences.

When was Panome Bio founded?

Panome Bio was founded in 2022.

Where is Panome Bio's headquarters located?

Panome Bio's headquarters is located in St. Louis, MO, US.

When was Panome Bio's last funding round?

Panome Bio's most recent funding round was for $6M (USD) in February 2023.

How much has Panome Bio raised to-date?

As of Feb 24, 2023, Panome Bio has raised a total of $6M (USD).

How many employees does Panome Bio have?

Panome Bio has 13 employees as of Feb 5, 2024.

Panome Bio - Classification

Ownership
  • Venture Capital
Technology
  • Analytics
Geographic Exposure
  • United States
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Biomarker Discovery
Tags
  • Biotech
  • Data
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software